Sienna Biopharmaceuticals Announces Its Topical, Non-Steroidal TRKA Inhibitor SNA-120 (0.05%) Demonstrated Significant Impact on Psoriasis in Phase 2B Study and Plans to Initiate Phase 3 Psoriasis Trials in Second Half of 2019

Source: Sienna Biopharmaceuticals WESTLAKE VILLAGE, Calif., Dec. 03, 2018 (GLOBE NEWSWIRE) -- Sienna Biopharmaceuticals, Inc. (NASDAQ:SNNA), a clinical-stage medical dermatology and aesthetics company, today announced top-line results from a Phase 2b study of SNA-120 (pegcantratinib), the Company’s lead drug candidate developed using its proprietary Topical by Design™ platform. This Phase 2b study, in mild-to-moderate…...